Each gram of Miotin dry syrup contains midecamycin acetate 200 mg (potency), methyl-p-oxybenzoate (preservative) 1 mg and propyl-p-oxybenzoate (preservative) 0.2 mg.
Midecamycin acetate is (4R,5S,6S,7R,9R,10R,11E,13E,16R)-10-acetyloxy-6-((3,6-dideoxy-4-O-(3-O-acetyl-2,6-dideoxy-3-C-methyl-4-O-propionyl-α-L-ribo-hexopyranosyl)-3-dimethylamino)-β-D-glucopyranosyl)oxy)-5-methoxy-9,16-dimethyl-4-propionyloxy-2-oxooxa-cyclohexadeca-11,13-diene-7-acetaldehyde.
Molecular Formula: C45H71NO17.
Molecular Weight: 898.05.
Melting Point: 210-217°C (decomposition point).
Potency: The potency is expressed as the weight of midecamycin acetate. 1 mg of standard midecamycin acetate contains 1 mg (potency) midecamycin acetate.
Midecamycin acetate is tasteless and odorless. It is very soluble in chloroform, freely soluble in acetone and ethyl acetate, sparingly soluble in methanol, slightly soluble in ethanol, and practically insoluble in water, ether and petroleum ether.
Miotin is a dry syrup preparation of midecamycin acetate which is a new acid-stable preparation synthesized from midecamycin by Meiji Seika Kaisha, Ltd.
Miotin dry syrup does not have the bitter taste characteristics of conventional macrolides and is easy to digest. Because the preparation is made in a noncrystalline form by a new preparation technique, it is well absorbed, attains high tissue concentrations for a prolonged period and shows excellent in vivo antibacterial activity.